1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
4D Molecular Therapeutics Inc. currently has 1 pending office action. This matter is assigned to 1 distinct examiner, ARON, KIMBERLY A. Interestingly, the data shows 0 distinct art units associated with this portfolio, which may indicate a unique administrative status or a very recent filing. ARON, KIMBERLY A is the busiest examiner with 1 busiest examiner pending action. This single action represents the company's entire active workload at the patent office. With only 1 distinct examiner involved, the prosecution process is highly centralized.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARON, KIMBERLY A | 1 | 54.7% | +34.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18766963 | CODON OPTIMIZED REP1 GENES AND USES THEREOF | ARON, KIMBERLY A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18766963 | CODON OPTIMIZED REP1 GENES AND USES THEREOF | ARON, KIMBERLY A | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18766963 | CODON OPTIMIZED REP1 GENES AND USES THEREOF | ARON, KIMBERLY A | — | §102§112Other | Non-Final OA | — | Pending | Jul 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial4D Molecular Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Kimberly A Aron has the most, with 1 of 4D Molecular Therapeutics Inc.'s pending office actions.
